These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30105745)

  • 1. Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method.
    Landfeldt E; Zethraeus N; Lindgren P
    Appl Health Econ Health Policy; 2019 Feb; 17(1):15-24. PubMed ID: 30105745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective.
    Hubens K; Krol M; Coast J; Drummond MF; Brouwer WBF; Uyl-de Groot CA; Hakkaart-van Roijen L
    Value Health; 2021 Nov; 24(11):1686-1699. PubMed ID: 34711370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' productivity losses and informal care costs related to ischemic stroke: a French population-based study.
    Barral M; Rabier H; Termoz A; Serrier H; Colin C; Haesebaert J; Derex L; Nighoghossian N; Schott AM; Viprey M;
    Eur J Neurol; 2021 Feb; 28(2):548-557. PubMed ID: 33047452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time costs associated with informal care for colorectal cancer: an investigation of the impact of alternative valuation methods.
    Hanly P; Céilleachair AÓ; Skally M; O'Leary E; Staines A; Kapur K; Fitzpatrick P; Sharp L
    Appl Health Econ Health Policy; 2013 Jun; 11(3):193-203. PubMed ID: 23549793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic burden of prostate cancer - a Swedish prevalence-based register study.
    Hao S; Östensson E; Eklund M; Grönberg H; Nordström T; Heintz E; Clements M
    BMC Health Serv Res; 2020 May; 20(1):448. PubMed ID: 32434566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of methods and applications to value informal care in economic evaluations of healthcare.
    Koopmanschap MA; van Exel JN; van den Berg B; Brouwer WB
    Pharmacoeconomics; 2008; 26(4):269-80. PubMed ID: 18370563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods.
    van den Berg B; Brouwer W; van Exel J; Koopmanschap M; van den Bos GA; Rutten F
    Soc Sci Med; 2006 Feb; 62(4):835-45. PubMed ID: 16137814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time.
    Grosse SD; Pike J; Soelaeman R; Tilford JM
    Pharmacoeconomics; 2019 Apr; 37(4):461-473. PubMed ID: 30953263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Analysis of Formal Care, Informal Care, and Productivity Losses in Primary Care Patients who Screened Positive for Dementia in Germany.
    Michalowsky B; Thyrian JR; Eichler T; Hertel J; Wucherer D; Flessa S; Hoffmann W
    J Alzheimers Dis; 2016; 50(1):47-59. PubMed ID: 26639964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to estimate productivity costs in economic evaluations.
    Krol M; Brouwer W
    Pharmacoeconomics; 2014 Apr; 32(4):335-44. PubMed ID: 24504850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The direct and indirect financial costs of informal cancer care: A scoping review.
    Coumoundouros C; Ould Brahim L; Lambert SD; McCusker J
    Health Soc Care Community; 2019 Sep; 27(5):e622-e636. PubMed ID: 31293013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care.
    Gervès C; Chauvin P; Bellanger MM
    Health Policy; 2014 May; 116(1):114-22. PubMed ID: 24461717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catastrophic financial effect of replacing informal care with formal care: a study based on haematological neoplasms.
    Ortega-Ortega M; Del Pozo-Rubio R
    Eur J Health Econ; 2019 Mar; 20(2):303-316. PubMed ID: 30121870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic valuation of informal care provided to people after a myocardial infarction in France.
    Rabier H; Serrier H; Schott AM; Mewton N; Ovize M; Nighoghossian N; Duclos A; Colin C
    BMC Health Serv Res; 2019 Oct; 19(1):763. PubMed ID: 31660961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland.
    Hanly P; Maguire R; Balfe M; O'Sullivan E; Sharp L
    Pharmacoeconomics; 2017 May; 35(5):591-601. PubMed ID: 28205149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the economic valuation and determining factors of informal care over time: the case of blood cancer.
    Ortega-Ortega M; Montero-Granados R; Jiménez-Aguilera JD
    Gac Sanit; 2018; 32(5):411-417. PubMed ID: 28529098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review.
    Oliva-Moreno J; Trapero-Bertran M; Peña-Longobardo LM; Del Pozo-Rubio R
    Pharmacoeconomics; 2017 Mar; 35(3):331-345. PubMed ID: 27848219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Economic Costs of Informal Care: Estimates from a National Cross-Sectional Survey in The Netherlands.
    Elayan S; Angelini V; Buskens E; de Boer A
    Eur J Health Econ; 2024 Nov; 25(8):1311-1331. PubMed ID: 38294595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Making visible the cost of informal caregivers' time in Latin America: a case study for major cardiovascular, cancer and respiratory diseases in eight countries.
    Espinola N; Pichon-Riviere A; Casarini A; Alcaraz A; Bardach A; Williams C; Rodriguez Cairoli F; Augustovski F; Palacios A
    BMC Public Health; 2023 Jan; 23(1):28. PubMed ID: 36604686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Productivity costs in economic evaluations: past, present, future.
    Krol M; Brouwer W; Rutten F
    Pharmacoeconomics; 2013 Jul; 31(7):537-49. PubMed ID: 23620213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.